Stock Price & Analysis

Based on recent analyst ratings and technical indicators, Elevance Health (ELV) shows mixed signals but leans towards a buying opportunity at current levels. The stock has maintained a neutral RSI of 50.87, suggesting balanced momentum, while trading near its 20-day moving average of $376.83.

Recent analyst coverage remains predominantly bullish, with multiple firms maintaining Buy ratings despite price target adjustments. Truist Securities maintains a Strong Buy rating with a $480 target, while Morgan Stanley sees significant upside potential with a $551 target, implying over 32% upside.

Based on technical analysis and market sentiment, Elevance Health (ELV) stock is projected to reach $415-420 by end of 2025, supported by strong healthcare sector fundamentals and positive momentum indicators showing RSI at balanced 50.87 level. The stock's Fibonacci resistance levels indicate potential upside to $415.29, with immediate support at $383.08, suggesting a bullish trajectory while maintaining stability. Recent market data and analyst coverage point to sustained growth potential for ELV, particularly as healthcare spending continues to rise and the company maintains its market leadership position in the managed care sector.

The S1 support level for ELV Stock is $378.82 ,The R1 resistant level for ELV Stock is $405.46.

As of the end of day on 2025-01-24, the price of ELV Stock was $400.91.

The target price for ELV Stock according to analyst rating is 501.46, with the highest price target at 625.00 and the lowest at 388.00. Analysts have a Strong Buy rating on ELV Stock overall.

The market cap of ELV is $93.0B.

Based on the provided data, ELV appears fairly valued with some potential upside. The current P/E ratio of 18.93 is reasonable for the healthcare sector, while the EV/EBITDA of 13.14 suggests moderate valuation levels. The company maintains healthy profit margins with a low P/S ratio of 0.70, indicating efficient revenue conversion.

Recent analyst consensus strongly supports this view, with multiple firms maintaining "Buy" ratings despite some price target adjustments. The average price target from recent analyst updates is around $500, suggesting approximately 20% upside potential from current levels.

The stock's current trading price of $387 represents a balanced entry point, supported by stable fundamentals and positive analyst sentiment. Recent price target revisions, while lower than previous targets, still indicate significant upside potential from current levels.

The company's strong market position in the healthcare sector and consistent dividend yield of 1.23% further support its current valuation levels.

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to Individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. It also offers infusible and injectable therapies. Carelon Services offers healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.

Based on technical analysis and market trends, Elevance Health (ELV) stock is projected to reach $575 by 2030, driven by the company's strong market position in healthcare services and consistent revenue growth. The healthcare sector's expansion and aging population demographics support a bullish long-term outlook for ELV. Technical indicators and fibonacci projections suggest multiple resistance levels will be broken over the next 5 years, with the stock likely maintaining its upward trajectory from current levels around $385.

ELV has a total of 104900 employees.